Abstract
The objective. To study the course of experimental allergic encephalomyelitis (EAE) after intravenous administration of hematopoietic stem cells (HSC) and suboccipital transplantation of fetal neurocells (FNC), and treatment impact on intensity of neural tissue renewing in rats with EAE. Materials and methods. The experiment included 40 rats, average weight 200 g. EAE was induced using complete Freund’s adjuvant. In 32 rats with EAE we used intravenous HSK (10 million cells or 20 million cells) and suboccipital transplantation of FNC (0.1 ml). The EAE clinical course was estimated up to 110 days. The rats were taken from the experiment on 23 rd , 25 th days and in 2 months after EAE induction. The preparations were stained by Nisse, with hematoxylin, eosin and picro-fuchsin. Morphological and morphometric studies were performed. Results. Complete recovery was not observed, and on the 26th day of the experiment EAE was regarded as a chronic process. After allogeneic HSC administration (in dose 10 million cells) peak of clinical manifestations was observed on the 20 th day of the experiment with animals’ gradual complete recovery. Administration of allogeneic HSC in a dose of 20 million cells leads to significantly more rapid regression of clinical signs compared to the treatment with allogeneic HSC in a dose of 10 million cells. Animals’ recovery after intravenous introduction of HSC and suboccipital transplantation of FNC was significantly more rapid than after treatment just with HSC. The treatment with intravenous introduction of HSC (20 million cells) and suboccipital transplantation of FNC was associated with temporary significant deterioration after HSC administration and rapid recovery after FNC application (on the 29 th day). In all treatment options we revealed the tendency to reduction of pathologically changed neurocyts and gliocyts number. Conclusion. Suboccipital administration of allogeneic FNC improves the clinical condition of rats with EAE. The best results of experimental EAE treatment were observed at intravenous administration of HSC (20 million cells) followed by FNC neurotransplantation, particularly on the 63 rd day.
Highlights
After allogeneic hematopoietic stem cells (HSC) administration peak of clinical manifestations was observed on the 20th day of the experiment with animals’ gradual complete recovery
Administration of allogeneic HSC in a dose of 20 million cells leads to significantly more rapid regression of clinical signs compared to the treatment with allogeneic HSC in a dose of 10 million cells
Ukrainian Neurosurgical Journal, 2017, No2 with intravenous introduction of HSC (20 million cells) and suboccipital transplantation of fetal neurocells (FNC) was associated with temporary significant deterioration after HSC administration and rapid recovery after FNC application
Summary
В основній групі 32 щурам внутрішньовенно вводили ГСК У групі No1 (без введення ГСК та ФН) одужання тварин не спостерігали, з 26-ї доби відзначений хронічний перебіг ЕАЕ. Тваринам групи No2 вводили ГСК у дозі 10 млн. Клітин, пік клінічних проявів ЕАЕ спостерігали на 20-ту добу з поступовим одужанням тварин. У щурів групи No3 введення ГСК у дозі 20 млн. Клітин статистично значуще сприяло швидшому регресу клінічних проявів у порівнянні з таким в групі No2. Клітин з подальшим інтратекальним введенням ФН) спостерігали тимчасове статистично значуще погіршення стану після введення ГСК та швидке покращення стану після введення ФН — на 29ту добу. Найбільш виражений позитивний вплив на перебіг захворювання, швидкість відновлення клінічного стану тварин і збереження нейронів відзначали при внутрішньовенному введенні 20 млн.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
